Lundbeck's 5-HT6 receptor blocker idalopirdine for Alzheimer's disease bombed in the phase III STARSHINE study, missing the primary endpoint of reducing cognitive decline as measured by the ADAS-Cog. The failure also spelled bad news for Axovant's 5-HT6 candidate intepirdine (RVT-101), sending its stock dropping, but the company said it remains optimistic about its data, which are set to report out in 2017. Axovant made headlines for raising $315 million at IPO, based on its ability to raise from the dead an abandoned GlaxoSmithKline compound. (FierceBiotech)
Ohio is dealing with overdoses due to the "elephant tranquilizer" carfentanil: an opioid that's 100 times stronger than the already potent fentanyl. (NPR)
The cannabidiol drug Epidiolex has passed its second phase III trial in Lennox-Gastaut syndrome, a rare epileptic disorder. The drug also worked in a phase III trial in Dravet syndrome, and GW Pharma is chomping at the bit to file its NDA. (Endpts)
A third denial for Remoxy: The FDA has sent Pain Therapeutics another complete response letter regarding its extended-release oxycodone capsule candidate. This time, the agency has problems with its purported abuse-deterrent properties.
The race is on to be first-to-market with a drug for tardive dyskinesia: it's Teva's deutetrabenazine versus Neurocrine's valbenazine. (Endpts)
Will the upcoming class of CGRP inhibitors revolutionize migraine treatment and prevention? (STAT News)
Neuraltus launched its second phase II study of NP001 in ALS, this time focusing on patients with higher levels of inflammation at baseline.